330 related articles for article (PubMed ID: 28428708)
21. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.
Chen PW; Mellon JK; Mayhew E; Wang S; He YG; Hogan N; Niederkorn JY
Exp Eye Res; 2007 Nov; 85(5):617-25. PubMed ID: 17870068
[TBL] [Abstract][Full Text] [Related]
22. IDO and intra-tumoral neutrophils were independent prognostic factors for overall survival for hepatocellular carcinoma.
Wang Y; Yao R; Zhang L; Xie X; Chen R; Ren Z
J Clin Lab Anal; 2019 Jun; 33(5):e22872. PubMed ID: 30843276
[TBL] [Abstract][Full Text] [Related]
23. Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy - meta-analysis.
Xu J; Li J; Chen J; Liu ZJ
Adv Clin Exp Med; 2015; 24(2):331-40. PubMed ID: 25931368
[TBL] [Abstract][Full Text] [Related]
24. Myeloid CD11c+ S100+ dendritic cells express indoleamine 2,3-dioxygenase at the inflammatory border to invasive lower lip squamous cell carcinoma.
Kuales MA; Wenzel J; Schmid-Wendtner MH; Bieber T; von Bubnoff D
Histol Histopathol; 2011 Aug; 26(8):997-1006. PubMed ID: 21692032
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
Brandacher G; Perathoner A; Ladurner R; Schneeberger S; Obrist P; Winkler C; Werner ER; Werner-Felmayer G; Weiss HG; Göbel G; Margreiter R; Königsrainer A; Fuchs D; Amberger A
Clin Cancer Res; 2006 Feb; 12(4):1144-51. PubMed ID: 16489067
[TBL] [Abstract][Full Text] [Related]
26. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
27. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
[TBL] [Abstract][Full Text] [Related]
28. Molecular docking and dynamic simulation studies evidenced plausible immunotherapeutic anticancer property by Withaferin A targeting indoleamine 2,3-dioxygenase.
Reddy SV; Reddy KT; Kumari VV; Basha SH
J Biomol Struct Dyn; 2015; 33(12):2695-709. PubMed ID: 25671592
[TBL] [Abstract][Full Text] [Related]
29. The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review.
Lin DJ; Ng JCK; Huang L; Robinson M; O'Hara J; Wilson JA; Mellor AL
Clin Otolaryngol; 2021 Sep; 46(5):919-934. PubMed ID: 34053179
[TBL] [Abstract][Full Text] [Related]
30. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
31. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection.
Larrea E; Riezu-Boj JI; Gil-Guerrero L; Casares N; Aldabe R; Sarobe P; Civeira MP; Heeney JL; Rollier C; Verstrepen B; Wakita T; Borrás-Cuesta F; Lasarte JJ; Prieto J
J Virol; 2007 Apr; 81(7):3662-6. PubMed ID: 17229698
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma.
Chen J; Gingold JA; Su X
Trends Mol Med; 2019 Nov; 25(11):1010-1023. PubMed ID: 31353124
[TBL] [Abstract][Full Text] [Related]
33. Persistent infectious diseases say - IDO. Role of indoleamine-2,3-dioxygenase in disease pathogenesis and implications for therapy.
Barth H; Raghuraman S
Crit Rev Microbiol; 2014 Nov; 40(4):360-8. PubMed ID: 23174025
[TBL] [Abstract][Full Text] [Related]
34. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
35. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.
Munn DH; Mellor AL
Trends Immunol; 2016 Mar; 37(3):193-207. PubMed ID: 26839260
[TBL] [Abstract][Full Text] [Related]
36. Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus.
Tanaka H; Tsukuma H; Yamano H; Oshima A; Shibata H
Int J Cancer; 2004 Dec; 112(6):1075-80. PubMed ID: 15386355
[TBL] [Abstract][Full Text] [Related]
37. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
Li H; Wu K; Tao K; Chen L; Zheng Q; Lu X; Liu J; Shi L; Liu C; Wang G; Zou W
Hepatology; 2012 Oct; 56(4):1342-51. PubMed ID: 22505239
[TBL] [Abstract][Full Text] [Related]
38. Characteristics and prognosis of patients in Japan with viral marker-negative hepatocellular carcinoma.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Yamaguchi A; Isogai M; Kaneoka Y; Washizu J
J Gastroenterol Hepatol; 2008 Mar; 23(3):459-66. PubMed ID: 17854425
[TBL] [Abstract][Full Text] [Related]
39. A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy.
Awuah SG; Zheng YR; Bruno PM; Hemann MT; Lippard SJ
J Am Chem Soc; 2015 Dec; 137(47):14854-7. PubMed ID: 26561720
[TBL] [Abstract][Full Text] [Related]
40. Gene expression profiling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling.
Ueda T; Honda M; Horimoto K; Aburatani S; Saito S; Yamashita T; Sakai Y; Nakamura M; Takatori H; Sunagozaka H; Kaneko S
Genomics; 2013 Apr; 101(4):238-48. PubMed ID: 23485556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
